Failure of the corona vaccine: CureVac with a high operating loss - shares on the NASDAQ initially in the black

Failure of the corona vaccine: CureVac with a high operating loss - shares on the NASDAQ initially in the black

According to a report by www.finanzen.net, the Tübingen biotech company CureVac continues to struggle with its failure with the corona vaccine. The company's operating loss in the first nine months of the year amounted to 186.2 million euros, compared to 127.9 million euros in the previous year. Sales fell from 55.7 million euros in the same period last year to 31.2 million euros by September 30th. Nevertheless, the company hopes to be able to bring its first product onto the market in the next few years.

The disappointment over the failed corona vaccine initially had a strong influence on the price development of the CureVac share, which then rose again by 2.27 percent towards the end of trading. The company is also focusing on the development of an mRNA-based cancer vaccine, with the aim of bringing the vaccination to market by 2028 at the earliest.

The available figures suggest that CureVac continues to struggle with the effects of its corona vaccine failure. The high losses and decline in sales may have a long-term impact on the company's financial stability. This could also lead to investments in further product development being affected. It remains to be seen how efforts in the area of ​​cancer vaccine development will develop and whether it will be possible to successfully develop this market segment.